King Pharmaceuticals, Wyeth and Jack Nicklaus Announce 3rd Annual Jack Nicklaus Heart And Stroke Challenge To Raise Money For Cardiovascular Research And Education

Bristol, TN and Collegeville, PA - June 14, 2006 - Legendary golfer Jack Nicklaus will hit the ceremonial first tee shot to open the 3rd Annual Jack Nicklaus Heart & Stroke Challenge. The focus of the Challenge is to raise awareness about the increasing risk of cardiovascular events such as heart attack and stroke among people age 55 and older. Cardiovascular disease is the nation's number one killer. Cardiovascular disease affects more than 70 million Americans, many of whom are over the age of 55.

"We are thrilled with this program and proud of the money we raised last year," said Mr. Nicklaus. "It is important for all of us to increase our awareness of our heart health and how we can take care of our hearts." A long-time hypertension patient, Mr. Nicklaus, who takes ALTACE® (ramipril) to help control his high blood pressure, worked with King Pharmaceuticals, Inc. and Wyeth Pharmaceuticals to create the program--an initiative that stresses the importance of people age 55 and older recognizing the increasing risk for cardiovascular events and talking to their doctors about what they can do to help reduce their risk.

At age 55 and older, heart health should be a priority.

• Men and women age 55 and older are at an increased risk for suffering a cardiovascular event such as heart attack, stroke and even cardiovascular-related death compared with those age 45 to 54.
  • Prevalence of stroke more than doubled for men.
  • Prevalence of cardiovascular disease more than doubled in women.
• 92% of deaths from heart attack occur after age 55.

The general public is invited to enter local golf tournaments at participating golf courses and will have the opportunity to donate money to The Larry King Cardiac Foundation by purchasing a "mulligan." Last year this event raised nearly $80,000, which was donated to The Larry King Cardiac Foundation. Each member from the two winning teams at each of the local golf courses participating in the Heart and Stroke Challenge will win a framed lithograph of Nicklaus' farewell at the British Open and will become eligible for a day of golf activities with Jack Nicklaus. Seven regional tournaments will be held in Colorado, Maryland, Virginia, New Jersey, Ohio, New York and Florida.

ABOUT ALTACE® (ramipril)
ALTACE is indicated in patients 55 years or older at high risk of developing a major cardiovascular event, either because of a history of coronary artery disease, stroke, or peripheral vascular disease or because of diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of stroke, myocardial infarction, or death from cardiovascular causes. ALTACE can be used in addition to other needed treatments (such as antihypertensive, antiplatelet, or lipid-lowering therapies). ALTACE is also indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. ALTACE is marketed by King Pharmaceuticals®, Inc. and Wyeth Pharmaceuticals.

IMPORTANT SAFETY INFORMATION
ALTACE should not be taken during pregnancy, as death or injury to the unborn child may result, or if a person has experienced serious side effects related to previous ACE inhibitors. Prescription ALTACE is not for everyone. ALTACE may cause swelling of the mouth, tongue, or throat, which could cause extremely serious risk and requires immediate medical care. There have been reports of low blood sugar in patients taking ALTACE with medicine for diabetes. Patients should contact their doctor if they have symptoms of low blood sugar such as sweating or shakiness. Common side effects include persistent dry cough, dizziness, and light-headedness due to low blood pressure. For more information about ALTACE and for a copy of important Product Information, please visit www.ALTACE.com.

ABOUT KING PHARMACEUTICALS®, INC.
King Pharmaceuticals, Inc., headquartered in Bristol, Tennessee, is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products. King Pharmaceuticals, Inc., an S&P 500 Index company, seeks to identify promising opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

ABOUT WYETH PHARMACEUTICALS
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines, and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.